OBJECTIVE: Our objective was to identify patient, study, and site factors associated with assay sensitivity in placebo-controlled neuropathic pain trials. METHODS: We examined the associations between study characteristics and standardized effect size (SES) in a database of 200 publicly available randomized clinical trials of pharmacologic treatments for neuropathic pain. RESULTS: There was considerable heterogeneity in the SESs among the examined trials. Univariate meta-regression analyses indicated that larger SESs were significantly associated with trials that had 1) greater minimum baseline pain inclusion criteria, 2) greater mean subject age, 3) a larger percentage of Caucasian subjects, and 4) a smaller total number of subjects. In a multiple meta-regression analysis, the associations between SES and minimum baseline pain inclusion criterion and age remained significant. CONCLUSIONS: Our analyses have examined potentially modifiable correlates of study SES and shown that a minimum pain inclusion criterion of 40 or above on a 0 to 100 scale is associated with a larger SES. These data provide a foundation for investigating strategies to improve assay sensitivity and thereby decrease the likelihood of falsely negative outcomes in clinical trials of efficacious treatments for neuropathic pain.
OBJECTIVE: Our objective was to identify patient, study, and site factors associated with assay sensitivity in placebo-controlled neuropathic pain trials. METHODS: We examined the associations between study characteristics and standardized effect size (SES) in a database of 200 publicly available randomized clinical trials of pharmacologic treatments for neuropathic pain. RESULTS: There was considerable heterogeneity in the SESs among the examined trials. Univariate meta-regression analyses indicated that larger SESs were significantly associated with trials that had 1) greater minimum baseline pain inclusion criteria, 2) greater mean subject age, 3) a larger percentage of Caucasian subjects, and 4) a smaller total number of subjects. In a multiple meta-regression analysis, the associations between SES and minimum baseline pain inclusion criterion and age remained significant. CONCLUSIONS: Our analyses have examined potentially modifiable correlates of study SES and shown that a minimum pain inclusion criterion of 40 or above on a 0 to 100 scale is associated with a larger SES. These data provide a foundation for investigating strategies to improve assay sensitivity and thereby decrease the likelihood of falsely negative outcomes in clinical trials of efficacious treatments for neuropathic pain.
Authors: Jesse A Berlin; Jill Santanna; Christopher H Schmid; Lynda A Szczech; Harold I Feldman Journal: Stat Med Date: 2002-02-15 Impact factor: 2.373
Authors: Robert H Dworkin; Dennis C Turk; Sarah Peirce-Sandner; Michael P McDermott; John T Farrar; Sharon Hertz; Nathaniel P Katz; Srinivasa N Raja; Bob A Rappaport Journal: Pain Date: 2010-03-03 Impact factor: 6.961
Authors: Richard E Harris; David A Williams; Samuel A McLean; Ananda Sen; Michael Hufford; R Michael Gendreau; Richard H Gracely; Daniel J Clauw Journal: Arthritis Rheum Date: 2005-11
Authors: Maija Haanpää; Nadine Attal; Miroslav Backonja; Ralf Baron; Michael Bennett; Didier Bouhassira; Giorgio Cruccu; Per Hansson; Jennifer A Haythornthwaite; Gian Domenico Iannetti; Troels S Jensen; Timo Kauppila; Turo J Nurmikko; Andew S C Rice; Michael Rowbotham; Jordi Serra; Claudia Sommer; Blair H Smith; Rolf-Detlef Treede Journal: Pain Date: 2010-09-19 Impact factor: 6.961
Authors: R H Dworkin; S Peirce-Sandner; D C Turk; M P McDermott; A Gibofsky; L S Simon; J T Farrar; N P Katz Journal: Osteoarthritis Cartilage Date: 2011-03-23 Impact factor: 6.576
Authors: Thomas Buchheit; Thomas Van de Ven; Hung-Lun John Hsia; Mary McDuffie; David B MacLeod; William White; Alexander Chamessian; Francis J Keefe; Chester Trip Buckenmaier; Andrew D Shaw Journal: Pain Med Date: 2016-01 Impact factor: 3.750
Authors: Christopher E Forsmark; Dana K Andersen; John T Farrar; Megan Golden; Aida Habtezion; Sohail Z Husain; Liang Li; Julia Mayerle; Stephen J Pandol; Aliye Uc; Zixi Zhu; Dhiraj Yadav Journal: Pancreas Date: 2018 Nov/Dec Impact factor: 3.327
Authors: Luana Colloca; Taylor Ludman; Didier Bouhassira; Ralf Baron; Anthony H Dickenson; David Yarnitsky; Roy Freeman; Andrea Truini; Nadine Attal; Nanna B Finnerup; Christopher Eccleston; Eija Kalso; David L Bennett; Robert H Dworkin; Srinivasa N Raja Journal: Nat Rev Dis Primers Date: 2017-02-16 Impact factor: 52.329
Authors: Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace Journal: Lancet Neurol Date: 2015-01-07 Impact factor: 44.182
Authors: Robert R Edwards; Robert H Dworkin; Dennis C Turk; Martin S Angst; Raymond Dionne; Roy Freeman; Per Hansson; Simon Haroutounian; Lars Arendt-Nielsen; Nadine Attal; Ralf Baron; Joanna Brell; Shay Bujanover; Laurie B Burke; Daniel Carr; Amy S Chappell; Penney Cowan; Mila Etropolski; Roger B Fillingim; Jennifer S Gewandter; Nathaniel P Katz; Ernest A Kopecky; John D Markman; George Nomikos; Linda Porter; Bob A Rappaport; Andrew S C Rice; Joseph M Scavone; Joachim Scholz; Lee S Simon; Shannon M Smith; Jeffrey Tobias; Tina Tockarshewsky; Christine Veasley; Mark Versavel; Ajay D Wasan; Warren Wen; David Yarnitsky Journal: Pain Date: 2016-09 Impact factor: 7.926
Authors: Nanna B Finnerup; Simon Haroutounian; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpaa; Troels S Jensen; Peter R Kamerman; Ewan McNicol; Andrew Moore; Srinivasa N Raja; Niels T Andersen; Emily S Sena; Blair H Smith; Andrew S C Rice; Nadine Attal Journal: Pain Date: 2018-11 Impact factor: 7.926